“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial comparing Stanford V chemotherapy with ABVD chemotherapy for advanced Hodgkin lymphoma
This trial compared standard ABVD combination chemotherapy with a newer combination of chemotherapy and radiotherapy called Stanford V for people with advanced Hodgkin lymphoma. This trial was supported by Cancer Research UK.
When this trial was done, earlier trial results suggested that a newer combination of chemotherapy and radiotherapy called Stanford V might be a useful treatment for advanced Hodgkin lymphoma. Standard V includes the drugs mustine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide and steroids.
The aim of this trial was to compare the standard treatment with the newer treatment to find out
- Which works best for advanced Hodgkin lymphoma
- More about the side effects
Summary of results
The trial team found that Stanford V combination chemotherapy with radiotherapy was no better than ABVD with radiotherapy for people with advanced Hodgkin lymphoma.
520 people took part in this trial
- Half had ABVD chemotherapy
- Half had Stanford V chemotherapy
After chemotherapy, some patients went on to have radiotherapy.
The trial team analysed the results in 2009. They looked at how well the treatment worked and how many people lived for five years after treatment. They found no difference between the 2 different groups.
The most common side effect in both groups was a drop in blood cell counts. People in the ABVD group had more lung problems.
The trial team concluded that there was no evidence that adding more chemotherapy drugs to the standard ABVD combination with radiotherapy helped to treat advanced Hodgkin lymphoma.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hoskin
Cancer Research UK
Chugai Pharma UK Ltd
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUK/02/002.